Form 4: Leap Therapeutics Chairman Settles Restricted Stock Units, Adjusts Holdings

Christopher Mirabelli, Chairman of the Board at Leap Therapeutics, settled restricted stock units (RSUs) and adjusted his beneficial ownership of company stock.

Summary

• On March 28, 2025, Christopher Mirabelli settled 22,500 restricted stock units (RSUs) previously granted on January 31, 2022.
• The settlement was executed on a net issue basis, with 15,828 shares issued to Mirabelli and 6,672 shares withheld to cover tax obligations at a price of $0.3166.
• Following the transaction, Mirabelli directly owns 20,914 shares of common stock.
• Mirabelli also has indirect ownership through Nine Capital Partners (2,136 shares), HealthCare Ventures IX, L.P. (414,480 shares), and the HCV VIII Trust (261,840 shares), but disclaims beneficial ownership except to the extent of his pecuniary interest.
• All share numbers have been adjusted to reflect a 10-for-1 reverse stock split that occurred on June 20, 2023.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports the settlement of RSUs, which is a routine transaction. There are no explicit positive or negative implications for the company's performance.

Positives

• The settlement of RSUs indicates that Mirabelli has met the vesting requirements, suggesting continued service with the company.
• The company withheld shares to cover tax obligations, simplifying the tax process for Mirabelli.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the settlement of previously granted equity compensation.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to align the interests of management with those of shareholders.
• The vesting and settlement terms of the RSUs appear standard, with provisions for tax withholding and potential deferral based on insider trading policies.
• Similar to other biotech companies, Leap Therapeutics uses RSUs as part of its compensation package to attract and retain key personnel.

Stakeholder Impact

• The settlement of RSUs has a minor dilutive effect on existing shareholders.
• The transaction provides insight into the compensation structure for key executives.

Key Dates

Keywords

LPTX, LEAP Therapeutics, Christopher Mirabelli, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, Insider Trading